Adult Rheumatoid Arthritis (RA): ORENCIA® (abatacept) is indicated for reducing signs and symptoms,
inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to
severely active RA. ORENCIA may be used as monotherapy or concomitantly with disease-modifying, anti-rheumatic drugs (DMARDs) other than tumor necrosis
factor (TNF) antagonists.
Juvenile Idiopathic Arthritis (JIA): ORENCIA is also indicated for reducing signs and symptoms in pediatric patients aged 6 years and older with
moderately to severely active polyarticular JIA. ORENCIA may be used as monotherapy or concomitantly with methotrexate (MTX).
Important Limitations of Use:
ORENCIA should not be administered concomitantly with TNF antagonists, and is not recommended for use
concomitantly with other biologic RA therapy, such as anakinra.